Accession Number : AD1031407

Title :   Exploring the Hypersensitivity of PTEN Deleted Prostate Cancer Stem Cells to WEE1 Tyrosine Kinase Inhibitors

Descriptive Note : Technical Report,30 Sep 2014,29 Sep 2015

Corporate Author : H. Lee Moffitt Cancer Center and Research Institute Tampa United States

Personal Author(s) : Mahajan,Kiran

Full Text :

Report Date : 01 Dec 2015

Pagination or Media Count : 41

Abstract : Central to all cycling cells-including prostate cancer stem cells- is the expression of WEE1 tyrosine kinase. WEE1 monitors duplication of the chromatin during each cell cycle to preserve genome stability and prevent mitotic catastrophe. PTEN (phosphatase and tensin homolog) is deleted at the 10q23.3 locus in 40 of human prostate cancers and is associated with aggressive metastatic disease with poor prognosis and androgen-independence. A PTEN null prostate cancer derived cell line, LNCaP, displays hypersensitivity and under goes significant cell death in response to treatment with the WEE1 inhibitor, MK1775. In contrast to LNCaP, MK1775 induces a differentiation like phenotype in the PTEN wild type prostate cancer derived cell line, LAPC4. Our hypothesis is that PTEN deletion results in hyper-proliferation phenotype in part due to the constitutive activation of the oncogenic AKT survival kinase and these cells requireWEE1 to ensure proper chromatin duplication. However, blocking WEE1 function, will force cells to enter mitosis with incompletely replicated chromatin leading to mitotic catastrophe. In contrast, LAPC4 cells, with regulated AKT activation will respond to WEE1inhibition by undergoing arrest at the G2/M border. This proposal will explore WEE1 kinase as a novel therapeutic target in PTEN mutated prostate cancer.

Descriptors :   stem cells , prostate cancer , Enzyme inhibitors , cell physiological processes , cell line , metastasis , neoplasms , tyrosine , therapeutics

Distribution Statement : APPROVED FOR PUBLIC RELEASE